ArticleAntioxidants (Basel, Switzerland)2024
Esculetin Combats Multidrug-Resistant
Article in Antioxidants (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Integrating Metabolomics and Transcriptomics Reveals the Multi-Target Mechanisms of FermentedNutrients · 2026Article
- Effects of esculetin on growth performance, carcass traits, intestinal morphology, digestive enzyme, barrier function and cecal microbiota in broiler chickens.Poultry science · 2026Article
- Esculetin and its derivatives: recent advances in efficacy, mechanisms, and translational challenges.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Therapeutic Agents Targeting the Nrf2 Signaling Pathway to Combat Oxidative Stress and Intestinal Inflammation in Veterinary and Translational Medicine.Veterinary sciences · 2025Review
- The role of plant-based dietary compounds in gut microbiota modulation in inflammatory bowel disease.Frontiers in nutrition · 2025Review
- Mechanisms of Keap1/Nrf2 modulation in bacterial infections: implications in persistence and clearance.Frontiers in immunology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The increasing incidence of multidrug-resistant (MDR)
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.